Monoclonal Antibody Hum195

What Monoclonal Antibody Hum195 Means in Everyday Medical Language

Monoclonal Antibody Hum195, also called lintuzumab or MoAb HuM195, is a laboratory-made protein designed to target a specific marker called CD33 found on the surface of many leukemia cells, especially in acute myeloid leukemia (AML), and some abnormal cells in myelodysplastic syndromes (MDS). By attaching to CD33, this antibody helps the immune system identify and attack these cancer cells.

Why It Can Matter in Cancer Care

Because many AML and related blood cancer cells carry the CD33 protein, lintuzumab was developed as a targeted therapy to focus treatment on these cancer cells while aiming to spare healthy cells. Targeted therapies like this try to attack cancer more precisely than traditional chemotherapy, which can affect many types of cells. However, clinical trials of lintuzumab have shown mixed results, and it has not become a standard treatment. Still, it has helped researchers understand how to target CD33 and contributed to newer therapies.

What Patients Might See or Hear About Monoclonal Antibody Hum195

Patients may encounter the names lintuzumab, MoAb HuM195, or Monoclonal Antibody Hum195 in medical records, treatment plans, or clinical trial descriptions. It may be mentioned as an experimental drug studied alone or with chemotherapy or other treatments. Seeing this term does not mean it is a recommended or approved treatment for everyone. It is important to ask your healthcare team what role it plays in your specific situation.

Where the Term Might Appear

This antibody may be listed in clinical trial information, research articles, or drug information pages. It might also appear in medical records or treatment plans if a patient is participating in a study or receiving an experimental therapy. Regulatory agencies have given lintuzumab orphan drug status for AML and MDS, recognizing it as a potential treatment for rare diseases, but it is not widely approved or used.

Common Confusions and Clarifications

Lintuzumab is sometimes called MoAb HuM195 or Monoclonal Antibody HuM195, which can be confusing since these names all refer to the same drug. Also, CD33 is found on some normal blood cells as well as leukemia cells, so lintuzumab is not a cure-all and does not replace other treatments. Patients should not assume that seeing the name lintuzumab means they have a specific diagnosis or that it is the best treatment option for them.

Practical Questions to Ask Your Care Team

If you come across this term, you might ask your healthcare providers what role lintuzumab plays in your treatment plan, whether it is part of a clinical trial, and what benefits and risks it might have for you. You can also ask how it compares to other treatment options and if there are any side effects to watch for.

How to Read the Term in Context

Because lintuzumab is mainly studied in research settings, it’s important to understand it as one piece of information within a larger treatment plan or clinical trial. It is not a standard treatment and may not be suitable for everyone. Always discuss with your care team what it means for your care.

Safety and Next Steps

This information is educational and does not decide what is safe or appropriate for any individual. If you see Monoclonal Antibody Hum195 or its other names in your medical records or discussions, the safest next step is to ask your healthcare team what it means in your specific case and how it fits into your overall treatment plan.